Drug Research
Allos recruits first patient in Phase 3 PTCL drug trial
Allos Therapeutics has recruited first patient in a Phase 3 multi-center, randomized, open-label (PDX-017) Phase 2 trial investigating Folotyn (pralatrexate injection) in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL). Folotyn is approved in the...
Drug Research
Abbott two new strengths of CPP drug gets FDA nod
Abbott has received the US Food and Drug Administration (FDA) approval for two new strengths of Lupron Depot-PED (leuprolide acetate for depot suspension) to treat children with central precocious puberty (CPP). The application was submitted...
Drug Research
AVI BioPharma starts patient dosing in DMG drug Phase 2 trial
AVI BioPharma has started patient dosing in a placebo-controlled Phase 2 trial to evaluate eteplirsen as a treatment for Duchenne muscular dystrophy (DMD).The study intends to investigate the safety and efficacy of eteplirsen in DMD patients over 24 weeks...
Drug Research
Biogen Idec, Abbott release Select Phase 2b RRMS drug trial results
Biogen Idec and Abbott have released top-line results from a double-blind, dose-ranging, randomized and placebo-controlled Select Phase 2b trial evaluating the experimental compound daclizumab high-yield process (DAC HYP) in patients with relapsing-remitting multiple sclerosis (RRMS) over one year. ...
Drug Research
Innovacyn introduces eye, ear formulations
Innovacyn, a provider of human and animal healthcare products, has added Vetericyn VF Ophthalmic Wash and Vetericyn VF Otic Rinse to its professional-strength animal healthcare line. The antimicrobial solution found in the Ophthalmic Wash and Otic...
Drug Research
Glenmark settles patent case with Daiichi, Genzyme
Glenmark Pharmaceuticals has settled patent litigation suit with Daiichi Sankyo and Genzyme in relation to its type-2 diabetes treatment Colesevelam Hydrochloride’s abbreviated new drug application (ANDA). With this settlement, Glenmark can roll out its generic...
Drug Research
RxMD signs drug development agreement with GlycoRegImmune
RxMD has collaborated with GlycoRegImmune (GRI) to develop new treatments by using GRI's novel natural killer (NK) T cell targeted technologies for autoimmune, inflammatory and neurodegenerative conditions. As per the terms of the agreement, RxMD will...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
